Bill would require Medicare to pay for off-label meds

Two U.S. Representatives have introduced a bill that would require Medicare to pay for off-label uses of all Part D drugs--as long as those uses are medically necessary and supported by published study data or standard medical practice. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.